RevBio, Inc. (#LSIEurope24 Innovator) is a clinical-stage medical device company developing and commercializing TETRANITE?, a patented, synthetic, injectable, self-setting, and osteoconductive adhesive biomaterial.
Initially, this novel technology will be indicated for use in dental, cranial, and broader orthopaedic applications as well as animal health. TETRANITE is not yet approved for commercial use, but with several regulatory-approved clinical trials underway, and more to come, the company is targeting a launch cadence of one product commercialization each year over the next five years.
RevBio has reached significant milestones, including:
? Received FDA approval to start a 20-patient pilot clinical trial to examine the safety and efficacy of the company’s bone adhesive biomaterial, TETRANITE? to immediately stabilize and fixate cranial flaps following craniotomy procedures associated with brain surgery.
? Announced the first 5 patients in its dental implant stabilization clinical trial have showcased positive healing.
? Received eligibility notice for conditional product approval from FDA’s Center for Veterinary Medicine
We’re excited to announce that Founder & CEO, Brian Hess has been selected to present RevBio at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Brian and learn more about RevBio.